FEB 27, 2019 12:00 PM PST

Evaluating Biomarkers for Response to Neoadjuvant Immune Checkpoint Blockade in Melanoma

SPONSORED BY: NanoString Technologies
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Director, Advanced Applications, NanoString
    Biography
      Sarah Warren is the director of advanced applications at NanoString and leads the early immuno-oncology research program. Prior to joining NanoString, she founded and ran Oncofactor Corp, a biotech focused on discovery of novel immune checkpoint inhibitors and development of therapeutics to block their activity. She has a PhD in immunology from the University of Washington and undergraduate degrees in biochemistry and English from Iowa State University.

    Abstract:

    Surgery is the first line of treatment for Stage III melanoma. Often adjuvant therapy is administered post-surgery, which can include weeks of radiation, chemotherapy, targeted drug therapy, or immunotherapy. Previous preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade may lead to increased survival compared to adjuvant treatment1. This webinar will cover recent data from parallel but independent clinical trials explored the efficacy of anti-PD-1 and/or anti-CLTA4 combination immunotherapy plus surgery in patients with early stage melanoma2,3. 

    In each study, safety of the treatment regimen and evidence of immune activity in response to treatment was evaluated. In addition to standard H&E and immunohistochemistry (IHC) staining before and after treatment each study also employed NanoString’s GeoMx™ Digital Spatial Profiler to perform high-plex proteomic analysis with spatial resolution. GeoMx DSP enabled the discovery of markers of antigen presentation (β2M) and T cells (CD3) present on pretreatment tumor biopsies that correlated with clinical efficacy in each study. Additionally, the responses to therapy in each study were strong enough to merit larger trials and continued investigation of the most effective immunotherapy strategy.

    FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

    Learning Objectives: 

    1. Gain an appreciation for how multiplexed spatial profiling via GeoMx can aid in tumor characterization
    2. Understand how GeoMx profiling was used in the 2 studies presented to identify biomarkers of response to immunotherapy and complement other molecular profiling strategies


    Show Resources
    You May Also Like
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    NOV 18, 2019 07:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    AUG 14, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 14, 2019 09:00 AM PDT
    DATE: August 14, 2019TIME: 9:00am PT. 12:00pm ET Implementation of Lean Methodology in Biobanking Operations to standardize sample management processes is effective. Each proce...
    Loading Comments...
    Show Resources
    Attendees